CXCR5 and Sjogren syndrome: Recently, paeoniflorin-6’-O-benzene (CP-25) has been found to limit the target organ index and B cell activities in experiment Sjögren’s syndrome (ESS) by inhibiting CXCR5-G protein-coupled receptor kinase 2 (GRK2)-ERK/p38 signaling pathway (162).